We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Read MoreHide Full Article
Key Takeaways
Yutrepia generated $300.3 million in first-half 2026 sales, driving Liquidia's fourth profitable quarter.
Liquidia plans to test Yutrepia in COPD, IPF, PPF and Raynaud's phenomenon tied to systemic sclerosis.
United Therapeutics and Insmed are advancing competing therapies that could intensify PAH market competition.
Liquidia Corporation (LQDA - Free Report) is counting on its lead drug, Yutrepia, to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology is designed to deliver the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
The FDA approved Yutrepia in May 2025 for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Since its commercial launch in June 2025, the drug has quickly emerged as Liquidia’s key growth driver, generating approximately $300.3 million in sales in the first half of 2026. Adoption has also been strong, with about 5,900 unique prescriptions since launch and more than 5,000 patients initiated on Yutrepia. Nearly 1,100 physicians have prescribed the therapy.
Strong Yutrepia sales have helped Liquidia deliver its fourth consecutive profitable quarter, underscoring the drug’s growing commercial traction.
However, sustaining this growth could prove challenging. The PAH market is highly competitive, with numerous established therapies targeting different disease pathways, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, activin signaling inhibitors and prostacyclin-based treatments. The availability of both branded and generic options, along with widespread combination use, creates a challenging environment for physician adoption and market share gains.
Liquidia is also seeking to broaden Yutrepia’s growth opportunity. The company plans to evaluate the therapy in pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon related to systemic sclerosis. Successful expansion into these additional indications could provide Yutrepia with new avenues for long-term growth.
LQDA Faces Competition in PAH Market
Yutrepia competes in the PAH market against several approved inhaled prostacyclin therapies, while additional pipeline candidates could intensify competition in the coming years.
Its primary competitor is United Therapeutics' (UTHR - Free Report) Tyvaso (treprostinil), the long-established inhaled therapy approved for PAH in 2009 and PH-ILD in 2021.
United Therapeutics also markets Tyvaso DPI, a dry-powder version of treprostinil approved in 2022 for both indications. Demand for this product has been strong.
United Therapeutics is further expanding its PAH franchise. The company highlighted two major regulatory filings — ralinepag tablets for PAH and nebulized Tyvaso for IPF — as potentially significant catalysts for long-term growth. Additional planned filings for ralinepag DPI and treprostinil SMI could further expand UTHR’s pipeline and growth opportunities.
Insmed (INSM - Free Report) is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148.
TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.The company has made encouraging progress with the program. INSM is currently enrolling patients in the PALM-ILD trial, a phase III study of TPIP in patients with PH-ILD. It is also actively enrolling patients in the PALM-PAH trial, a phase III study of TPIP in those with PAH.
Last month, the company reported positive 12-month data from the ongoing open-label extension study of TPIP in patients with PAH.
The company also plans to initiate a phase III study of TPIP in patients with PPF in the second half of 2026, followed by a phase III study in IPF in the first half of 2027.
Insmed is advancing INS1148 in a phase II program initially focused on PPF and IPF. The company is also exploring additional diseases where inhibiting the inflammatory functions of Stem Cell Factor 248 (SCF248) could provide therapeutic benefits.
Although Yutrepia's proprietary PRINT technology, strong launch trajectory and increasing physician adoption position it well to gain additional market share, its ability to sustain long-term growth will depend on continued execution, successful differentiation from established therapies and expansion of its presence in an increasingly competitive PAH treatment landscape.
Shares of LQDA have surged 96.3% year to date compared with the industry’s growth of 8.9%.
Image Source: Zacks Investment Research
Going by the price/sales ratio, LQDA shares currently trade at 6.16X forward sales, higher than the industry’s average of 1.93X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97, and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Key Takeaways
Liquidia Corporation (LQDA - Free Report) is counting on its lead drug, Yutrepia, to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology is designed to deliver the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
The FDA approved Yutrepia in May 2025 for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Since its commercial launch in June 2025, the drug has quickly emerged as Liquidia’s key growth driver, generating approximately $300.3 million in sales in the first half of 2026. Adoption has also been strong, with about 5,900 unique prescriptions since launch and more than 5,000 patients initiated on Yutrepia. Nearly 1,100 physicians have prescribed the therapy.
Strong Yutrepia sales have helped Liquidia deliver its fourth consecutive profitable quarter, underscoring the drug’s growing commercial traction.
However, sustaining this growth could prove challenging. The PAH market is highly competitive, with numerous established therapies targeting different disease pathways, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, activin signaling inhibitors and prostacyclin-based treatments. The availability of both branded and generic options, along with widespread combination use, creates a challenging environment for physician adoption and market share gains.
Liquidia is also seeking to broaden Yutrepia’s growth opportunity. The company plans to evaluate the therapy in pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon related to systemic sclerosis. Successful expansion into these additional indications could provide Yutrepia with new avenues for long-term growth.
LQDA Faces Competition in PAH Market
Yutrepia competes in the PAH market against several approved inhaled prostacyclin therapies, while additional pipeline candidates could intensify competition in the coming years.
Its primary competitor is United Therapeutics' (UTHR - Free Report) Tyvaso (treprostinil), the long-established inhaled therapy approved for PAH in 2009 and PH-ILD in 2021.
United Therapeutics also markets Tyvaso DPI, a dry-powder version of treprostinil approved in 2022 for both indications. Demand for this product has been strong.
United Therapeutics is further expanding its PAH franchise. The company highlighted two major regulatory filings — ralinepag tablets for PAH and nebulized Tyvaso for IPF — as potentially significant catalysts for long-term growth. Additional planned filings for ralinepag DPI and treprostinil SMI could further expand UTHR’s pipeline and growth opportunities.
Insmed (INSM - Free Report) is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148.
TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.The company has made encouraging progress with the program. INSM is currently enrolling patients in the PALM-ILD trial, a phase III study of TPIP in patients with PH-ILD. It is also actively enrolling patients in the PALM-PAH trial, a phase III study of TPIP in those with PAH.
Last month, the company reported positive 12-month data from the ongoing open-label extension study of TPIP in patients with PAH.
The company also plans to initiate a phase III study of TPIP in patients with PPF in the second half of 2026, followed by a phase III study in IPF in the first half of 2027.
Insmed is advancing INS1148 in a phase II program initially focused on PPF and IPF. The company is also exploring additional diseases where inhibiting the inflammatory functions of Stem Cell Factor 248 (SCF248) could provide therapeutic benefits.
Although Yutrepia's proprietary PRINT technology, strong launch trajectory and increasing physician adoption position it well to gain additional market share, its ability to sustain long-term growth will depend on continued execution, successful differentiation from established therapies and expansion of its presence in an increasingly competitive PAH treatment landscape.
LQDA’s Share Price Performance, Valuation & Estimates
Shares of LQDA have surged 96.3% year to date compared with the industry’s growth of 8.9%.
Image Source: Zacks Investment Research
Going by the price/sales ratio, LQDA shares currently trade at 6.16X forward sales, higher than the industry’s average of 1.93X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97, and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.
Image Source: Zacks Investment Research
LQDA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.